ALXA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALXA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Alexza Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2016 was $-13.45 Mil. Alexza Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2016 was $12.66 Mil. Therefore, Alexza Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2016 was -106.25%.
The historical rank and industry rank for Alexza Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
The historical data trend for Alexza Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexza Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -69.23 | -62.76 | -90.42 | -67.63 | -55.87 |
Alexza Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | |
Return-on-Tangible-Asset | Get a 7-Day Free Trial | -3.09 | -131.39 | -73.92 | -58.96 | -106.25 |
For the Drug Manufacturers - Specialty & Generic subindustry, Alexza Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Alexza Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Alexza Pharmaceuticals's Return-on-Tangible-Asset falls into.
Alexza Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2015 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(A: Dec. 2015 ) | (A: Dec. 2014 ) | (A: Dec. 2015 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(A: Dec. 2015 ) | (A: Dec. 2014 ) | (A: Dec. 2015 ) | |||||
= | -21.31 | / | ( (61.56 | + | 14.731) | / 2 ) | |
= | -21.31 | / | 38.1455 | ||||
= | -55.87 % |
Alexza Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2016 is calculated as:
Return-on-Tangible-Asset | = | Net Income | / | ( (Total Tangible Assets | + | Total Tangible Assets) | / count ) |
(Q: Mar. 2016 ) | (Q: Dec. 2015 ) | (Q: Mar. 2016 ) | |||||
= | Net Income | / | ( (Total Assets - Intangible Assets | + | Total Assets - Intangible Assets) | / count ) | |
(Q: Mar. 2016 ) | (Q: Dec. 2015 ) | (Q: Mar. 2016 ) | |||||
= | -13.448 | / | ( (14.731 | + | 10.583) | / 2 ) | |
= | -13.448 | / | 12.657 | ||||
= | -106.25 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2016) net income data.
Alexza Pharmaceuticals (OTCPK:ALXA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Thank you for viewing the detailed overview of Alexza Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Deepika Pakianathan | director | 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402 |
Gordon Ringold | director | 325 EAST MIDDLEFIELD AVENUE, MOUNTAIN VIEW CA 94043 |
J Kevin Buchi | director | 41 MOORES ROAD, FRAZER PA 19355 |
Thomas Braxton King | director, officer: President & CEO | 91 JAMES AVENUE, ATHERTON CA 94027 |
Joseph L Turner | director | 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Mark K Oki | officer: Former SVP, CFO, Secretary | C/O ALEXZA PHARMACEUTICALS INC, 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
Robert A Lippe | officer: EVP, Operations & COO | C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
James V Cassella | director, officer: Former EVP, R&D and CSO | 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043 |
Samuel D Colella | other: Former Director | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Alan D Frazier | director | |
Symphony Capital Gp, L.p. | 10 percent owner, other: See Footnote 2 and Remarks | C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022 |
Harri V Taranto | 10 percent owner, other: See Footnote 2 and Remarks | C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022 |
Symphony Gp, Llc | 10 percent owner, other: See Footnote 2 and Remarks | C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, 18TH FLOOR, NEW YORK NY 10022 |
Symphony Capital Partners Lp | 10 percent owner, other: See Footnote 2 and Remarks | C/O SYMPHONY CAPITAL LLC, 875 THIRD AVENUE, NEW YORK NY 10022 |
Mark Kessel | 10 percent owner, other: See Footnote 2 and Remarks | 950 PARK AVE APT. 11A, NEW YORK NY 10028 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 12-21-2009
By GuruFocus Research GuruFocus Editor • 05-07-2010
By alicet236 alicet236 • 07-29-2013
By GuruFocus Research GuruFocus Editor • 12-21-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.